PR Newswire07.20.18
Companion Medical, a leader in the development of advanced technology to improve diabetes care, has received CE mark for the InPen system, paving the way for launch in key international markets. The InPen system is commercially available in the U.S. and is the only FDA-cleared, smart insulin pen paired with an integrated diabetes management app.
"We look forward to introducing more sophisticated smart pen technology with integrated diabetes management tools to people with diabetes in Europe," said CEO Sean Saint. "Our mission is to empower people living with diabetes and their healthcare providers with easy-to-use solutions that improve outcomes at a lower cost. With diabetes, the greatest challenge is knowing how much insulin to take and when to take it. The InPen system gives people with diabetes the tools they need to answer those questions precisely and accurately. Healthcare providers need actionable, reliable data from their insulin pen users, and now finally have that through Insights by InPen, our integrated diabetes management report."
The Insights by InPen report displays aggregated glucose, insulin, and meal data with detailed daily views, enabling providers to monitor glucose control and adherence patterns, identify the causes and effects of key decisions, and make targeted improvements to therapy.
Companion Medical intends to bring the benefits of the InPen system to Europe in 2019. Currently, more than 90 percent of insulin delivered around the world is administered through pens and syringes. Durable insulin pens are particularly well utilized in Europe, providing an obvious and significant opportunity for InPen. Given that insulin pump therapy comprises less than 10 percent of US insulin delivery and even less in Europe, Companion Medical's advanced insulin and disease management technology for pen users fulfills a tremendous unmet need.
InPen is available in the U.S. by prescription only. The app is available for download on the Apple App Store with launch in the Android marketplace expected later this year.
"We look forward to introducing more sophisticated smart pen technology with integrated diabetes management tools to people with diabetes in Europe," said CEO Sean Saint. "Our mission is to empower people living with diabetes and their healthcare providers with easy-to-use solutions that improve outcomes at a lower cost. With diabetes, the greatest challenge is knowing how much insulin to take and when to take it. The InPen system gives people with diabetes the tools they need to answer those questions precisely and accurately. Healthcare providers need actionable, reliable data from their insulin pen users, and now finally have that through Insights by InPen, our integrated diabetes management report."
The Insights by InPen report displays aggregated glucose, insulin, and meal data with detailed daily views, enabling providers to monitor glucose control and adherence patterns, identify the causes and effects of key decisions, and make targeted improvements to therapy.
Companion Medical intends to bring the benefits of the InPen system to Europe in 2019. Currently, more than 90 percent of insulin delivered around the world is administered through pens and syringes. Durable insulin pens are particularly well utilized in Europe, providing an obvious and significant opportunity for InPen. Given that insulin pump therapy comprises less than 10 percent of US insulin delivery and even less in Europe, Companion Medical's advanced insulin and disease management technology for pen users fulfills a tremendous unmet need.
InPen is available in the U.S. by prescription only. The app is available for download on the Apple App Store with launch in the Android marketplace expected later this year.
